Cosmos Health Sees FY27 Revenue To Increase By 163%, From $59.35M In 2024 To $155.80M In 2027; Gross Profit To Grow By 653%, From $6.25M In 2024 To $47.06M In 2027; Gross Profit Margin To Expand By 1,970 Basis Points, From 10.50% In 2024 To 30.20% In...
Cosmos Health Sees FY27 Revenue To Increase By 163%, From $59.35M In 2024 To $155.80M In 2027; Gross Profit To Grow By 653%, From $6.25M In 2024 To $47.06M In 2027; Gross Profit Margin To Expand By 1,970 Basis Points, From 10.50% In 2024 To 30.20% In...
阿童木健康预计2027财年营业收入将增长163%，从2024年的5935万美元增至2027年的15580万美元；毛利润预计将增长653%，从2024年的625万美元增至2027年的4706万美元；毛利润率预计将扩大1970个基点，从2024年的10.50%增至2027年的30.20%。
Cosmos Health Sees FY27 Revenue To Increase By 163%, From $59.35M In 2024 To $155.80M In 2027; Gross Profit To Grow By 653%, From $6.25M In 2024 To $47.06M In 2027; Gross Profit Margin To Expand By 1,970 Basis Points, From 10.50% In 2024 To 30.20% In 2027; Net Income To Increase By 402%, Reaching $20.44M In 2027, Compared To A Loss Of $6.76M In 2024; Adjusted EBITDA To Grow To $29.40M In 2027, From A Loss Of $1.21M In 2024.
阿童木健康预计2027财年营业收入将增长163%，从2024年的5935万美元增加到2027年的15580万美元；毛利润将增长653%，从2024年的625万美元增加到2027年的4706万美元；毛利润率将增加1970个基点，从2024年的10.50%增加到2027年的30.20%；净利润将增长402%，达到2027年的2044万美元，而2024年为亏损676万美元；调整后的EBITDA将从2024年的121万美元亏损增长至2027年的2940万美元。
Updated Financial Guidance
更新后的财务指导方针
We are pleased to see the pieces of our multi-year strategy coming together, which has made us confident in communicating our 2024-2027 guidance. By 2027, we anticipate substantial value creation by achieving the following:
我们很高兴看到我们跨年度策略的各个部分正在融合在一起，这让我们对沟通我们的2024年至2027年指导方针充满信心。到2027年，我们预计通过实现以下目标实现大量价值创造：
Revenue to increase by 163%, from $59.35 million in 2024 to...
营业收入将增长1...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
资讯热榜
更新时间